ST ALEXIUS MEDICAL CENTER
- Type
- Teaching hospital
- Where
- BISMARCK, ND
- Medicare CCN
- 350002
- Received
- $47,892 in 32 records, 2019 ($0 general, $47,892 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: ST ALEXIUS MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: ST. ALEXIUS MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: ST. ALEXIUS MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: ST ALEXIUS MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | Research payment | 32 | $47,892 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Boston Scientific Corporation | 15 | $23,146 | 2019 |
| PUMA BIOTECHNOLOGY, INC. | 3 | $8,250 | 2019 |
| Incyte Corporation | 3 | $7,202 | 2019 |
| Novartis Pharmaceuticals Corporation | 1 | $3,858 | 2019 |
| Allergan, Inc. | 3 | $3,006 | 2019 |
| ABBVIE INC. | 3 | $1,412 | 2019 |
| AstraZeneca Pharmaceuticals LP | 1 | $540 | 2019 |
| VIVUS LLC | 3 | $474 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 32 | $47,892 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-23 | Boston Scientific Corporation | $1,010 | Research payment | In-kind items and services | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | LONGEVITY STUDY | 2019 |
| 2019-12-19 | PUMA BIOTECHNOLOGY, INC. | $7,150 | Research payment | Cash or cash equivalent | Nerlynx Drug, Oncology | A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib | 2019 |
| 2019-11-13 | Boston Scientific Corporation | $3,506 | Research payment | Cash or cash equivalent | UPHOLD LITE Device, PELVIC ORGAN PROLAPSE | UPHOLD LITE | 2019 |
| 2019-10-31 | Boston Scientific Corporation | $760 | Research payment | In-kind items and services | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | LONGEVITY STUDY | 2019 |
| 2019-09-16 | Boston Scientific Corporation | $190 | Research payment | Cash or cash equivalent | UPHOLD LITE Device, PELVIC ORGAN PROLAPSE | UPHOLD LITE | 2019 |
| 2019-08-07 | Boston Scientific Corporation | $2,337 | Research payment | Cash or cash equivalent | UPHOLD LITE Device, PELVIC ORGAN PROLAPSE | UPHOLD LITE | 2019 |
| 2019-07-18 | Boston Scientific Corporation | $255 | Research payment | In-kind items and services | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | LONGEVITY STUDY | 2019 |
| 2019-06-27 | Allergan, Inc. | $1,171 | Research payment | Cash or cash equivalent | ZENPEP Drug, CYSTIC FIBROSIS | LONG-TERM STUDY IN US CYSTIC FIBROSIS PATIENTS RECEIVING DIGESTIVE ENZYME SUPPLEMENTS TO ASSESS ANY NARROWING OF THE LAR | 2019 |
| 2019-06-27 | ABBVIE INC. | $550 | Research payment | Cash or cash equivalent | Creon Drug, Endocrinology | P12-792 | 2019 |
| 2019-06-27 | VIVUS LLC | $185 | Research payment | Cash or cash equivalent | PANCREAZE Drug, CYSTIC FIBROSIS | Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large I | 2019 |
| 2019-06-25 | Boston Scientific Corporation | $3,506 | Research payment | Cash or cash equivalent | UPHOLD LITE Device, PELVIC ORGAN PROLAPSE | UPHOLD LITE | 2019 |
| 2019-06-10 | Incyte Corporation | $44 | Research payment | Cash or cash equivalent | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2019 | |
| 2019-05-23 | Boston Scientific Corporation | $255 | Research payment | In-kind items and services | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | LONGEVITY STUDY | 2019 |
| 2019-05-15 | Boston Scientific Corporation | $300 | Research payment | Cash or cash equivalent | UPHOLD LITE Device, PELVIC ORGAN PROLAPSE | UPHOLD LITE | 2019 |
| 2019-05-13 | Boston Scientific Corporation | $3,281 | Research payment | Cash or cash equivalent | UPHOLD LITE Device, PELVIC ORGAN PROLAPSE | UPHOLD LITE | 2019 |
| 2019-04-29 | Incyte Corporation | $475 | Research payment | Cash or cash equivalent | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2019 | |
| 2019-04-25 | Allergan, Inc. | $350 | Research payment | Cash or cash equivalent | ZENPEP Drug, CYSTIC FIBROSIS | LONG-TERM STUDY IN US CYSTIC FIBROSIS PATIENTS RECEIVING DIGESTIVE ENZYME SUPPLEMENTS TO ASSESS ANY NARROWING OF THE LAR | 2019 |
| 2019-04-25 | ABBVIE INC. | $164 | Research payment | Cash or cash equivalent | Creon Drug, Endocrinology | P12-792 | 2019 |
| 2019-04-25 | VIVUS LLC | $55 | Research payment | Cash or cash equivalent | PANCREAZE Drug, CYSTIC FIBROSIS | Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large I | 2019 |
| 2019-04-18 | PUMA BIOTECHNOLOGY, INC. | $900 | Research payment | Cash or cash equivalent | Nerlynx Drug, Oncology | A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib | 2019 |
| 2019-04-12 | Boston Scientific Corporation | $1,843 | Research payment | Cash or cash equivalent | UPHOLD LITE Device, PELVIC ORGAN PROLAPSE | UPHOLD LITE | 2019 |
| 2019-03-19 | Boston Scientific Corporation | $1,350 | Research payment | Cash or cash equivalent | UPHOLD LITE Device, PELVIC ORGAN PROLAPSE | UPHOLD LITE | 2019 |
| 2019-03-12 | AstraZeneca Pharmaceuticals LP | $540 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Eval | 2019 |
| 2019-02-28 | PUMA BIOTECHNOLOGY, INC. | $200 | Research payment | Cash or cash equivalent | Nerlynx Drug, Oncology | A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib | 2019 |
| 2019-02-21 | Boston Scientific Corporation | $1,270 | Research payment | In-kind items and services | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | LONGEVITY STUDY | 2019 |
| 2019-02-20 | Novartis Pharmaceuticals Corporation | $3,858 | Research payment | Cash or cash equivalent | GILENYA Drug, NEUROSCIENCE | LONG TERM PROSPECTIVE MULTINATIONAL PARALLEL COHORT STUDY MONITORING SAFETY IN PATIENTS WITH MULTIPLE SCLEROSIS NEWLY ST | 2019 |
| 2019-02-06 | Boston Scientific Corporation | $2,187 | Research payment | Cash or cash equivalent | UPHOLD LITE Device, PELVIC ORGAN PROLAPSE | UPHOLD LITE | 2019 |
| 2019-02-05 | Incyte Corporation | $6,682 | Research payment | Cash or cash equivalent | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2019 | |
| 2019-01-17 | Allergan, Inc. | $1,484 | Research payment | Cash or cash equivalent | ZENPEP Drug, CYSTIC FIBROSIS | LONG-TERM STUDY IN US CYSTIC FIBROSIS PATIENTS RECEIVING DIGESTIVE ENZYME SUPPLEMENTS TO ASSESS ANY NARROWING OF THE LAR | 2019 |
| 2019-01-17 | ABBVIE INC. | $697 | Research payment | Cash or cash equivalent | Creon Drug, Endocrinology | P12-792 | 2019 |
| 2019-01-17 | VIVUS LLC | $234 | Research payment | Cash or cash equivalent | PANCREAZE Drug, CYSTIC FIBROSIS | Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large I | 2019 |
| 2019-01-15 | Boston Scientific Corporation | $1,093 | Research payment | Cash or cash equivalent | UPHOLD LITE Device, PELVIC ORGAN PROLAPSE | UPHOLD LITE | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Bismarck, ND, county Burleigh County, ND, state North Dakota; placed by its city name.
| Measure | Place (city or town) Bismarck, ND | County Burleigh County, ND | State North Dakota |
|---|---|---|---|
| Population B01003 | 75,556 | 100,600 | 784,841 |
| Population, 2020 census P1 | 73,622 | 98,458 | 779,094 |
| Median age B01002 | 38.9 | 38.5 | 35.9 |
| Under 18 B01001 | 21.5% | 23.2% | 23.5% |
| 65 and over B01001 | 19.5% | 17.9% | 16.5% |
| Households B11001 | 33,130 | 41,269 | 331,063 |
| Foreign born B05002 | 4.0% | 3.3% | 4.7% |
| Median household income B19013 | $78,387 | $86,851 | $76,657 |
| Median family income B19113 | $109,530 | $115,645 | $104,993 |
| Per capita income B19301 | $45,788 | $45,977 | $43,389 |
| Poverty rate B17001 | 9.3% | 7.9% | 10.8% |
| Unemployment rate B23025 | 2.5% | 2.3% | 2.8% |
| Civilian labor force B23025 | 39,606 | 52,789 | 417,808 |
| Mean commute (minutes) B08013 | 15.6 | 17.5 | 17.9 |
| Bachelor's degree or higher B15003 | 39.2% | 39.1% | 32.7% |
| Housing units B25001 | 35,361 | 43,779 | 377,281 |
| Owner-occupied B25003 | 65.5% | 71.2% | 62.9% |
| Renters B25003 | 34.5% | 28.8% | 37.1% |
| Median home value B25077 | $300,300 | $324,000 | $249,900 |
| Median gross rent B25064 | $999 | $998 | $954 |
| White, not Hispanic B03002 | 82.8% | 84.9% | 81.7% |
| Black B03002 | 2.5% | 1.9% | 3.3% |
| Hispanic or Latino B03002 | 3.5% | 3.4% | 4.7% |
| Asian B03002 | 1.2% | 1.0% | 1.6% |
| American Indian and Alaska Native B03002 | 4.0% | 3.3% | 4.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Bismarck, ND.
Comments